Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 2/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11711444 | 0.96 | PTGER2 (0.41) | PTGER2PTGER4PTGER1PTGER3 | |
| SCHEMBL7886844 | 0.96 | PTGER2 (0.41) | PTGER2PTGER4PTGER1PTGER3 | |
| SCHEMBL5075349 | 0.83 | PTGER4 (0.52) | PTGER2PTGER4 | |
| SCHEMBL11712452 | 0.79 | PTGFR (0.38) | PTGER2PTGER1PTGER3 | |
| SCHEMBL7946133 | 0.79 | MGLL (0.36) | — | |
| SCHEMBL11719161 | 0.79 | PTGFR (0.38) | PTGER2PTGER1PTGER3 | |
| SCHEMBL11712438 | 0.79 | PTGFR (0.38) | PTGER2PTGER1PTGER3 | |
| SCHEMBL11711762 | 0.79 | PTGER4 (0.50) | PTGER2PTGER4PTGER3 | |
| SCHEMBL11711459 | 0.79 | FAAH (0.33) | PTGER2PTGER4 | |
| SCHEMBL6683022 | 0.78 | PTGER3 (0.53) | PTGER2PTGER4PTGER1PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7255984-B2 | Combination therapy for osteoporosis | PFIZER INC. (US) | 2007-08-14 | — | — | US | claimed |
| US-20040254230-A1 | Method for treating ocular hypertension | MERCK FROSST CANADA LTD. (CA) | 2004-12-16 | — | — | US | claimed |
| EP-1461026-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2004-09-29 | — | — | EP | claimed |
| WO-2003047513-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | claimed |
| US-20010009920-A1 | Estrogen agonist/antagonist and a prostaglandin or a prostaglandin agonist/antagonist | KE HUA ZHU (US) | 2001-07-26 | — | — | US | claimed |
| EP-0883404-A1 | COMBINATION THERAPY FOR OSTEOPOROSIS | PFIZER INC. (US) | 1998-12-16 | — | — | EP | claimed |
| WO-1997031640-A1 | COMBINATION THERAPY FOR OSTEOPOROSIS | PFIZER INC. (US) | 1997-09-04 | — | — | WO | claimed |
| EP-1932543-A2 | Combination therapy for osteoporosis consisting of an estrogen agonist/antagonist and a growth hormone secretagogue | Pfizer, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| US-7255984-B2 | Combination therapy for osteoporosis | PFIZER INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-20040254230-A1 | Method for treating ocular hypertension | MERCK FROSST CANADA LTD. (CA) | 2004-12-16 | — | — | US | disclosed |
| EP-1461026-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003047513-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-1236475-A2 | Combination therapy for osteoporosis consisting of an estrogen agonist/antagonist and a growth hormone secretagogue | PFIZER INC. (US) | 2002-09-04 | — | — | EP | disclosed |
| US-6323232-B1 | TREATMENT OF OSTEOPOROSIS WITH LASOFOXIFENE AND PGE2 | PFIZER INC. | 2001-11-27 | — | — | US | disclosed |
| US-20010009920-A1 | Estrogen agonist/antagonist and a prostaglandin or a prostaglandin agonist/antagonist | KE HUA ZHU (US) | 2001-07-26 | — | — | US | disclosed |
| EP-0883404-A1 | COMBINATION THERAPY FOR OSTEOPOROSIS | PFIZER INC. (US) | 1998-12-16 | — | — | EP | disclosed |
| WO-1997031640-A1 | COMBINATION THERAPY FOR OSTEOPOROSIS | PFIZER INC. (US) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009920-A1 | Estrogen agonist/antagonist and a prostaglandin or a prostaglandin agonist/antagonist | PTGER1, PTGER2, PTGER4 | PTGER2 2/4885PTGER4 3/4885PTGER1 1/4885 |
| US-20040254230-A1 | Method for treating ocular hypertension | PTGIR, PTGER4, PTGER1 | PTGER2 4/4885PTGER4 2/4885PTGER1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.